Search results for " PROGRESS"

showing 10 items of 1287 documents

Modeling interactions between Human Equilibrative Nucleoside Transporter-1 and other factors involved in the response to gemcitabine treatment to pre…

2014

Background Pancreatic ductal adenocarcinoma (PDAC) is an extremely aggressive malignancy, characterized by largely unsatisfactory responses to the currently available therapeutic strategies. In this study we evaluated the expression of genes involved in gemcitabine uptake in a selected cohort of patients with PDAC, with well-defined clinical-pathological features. Methods mRNA levels of hENT1, CHOP, MRP1 and DCK were evaluated by means of qRT-PCR in matched pairs of tumor and adjacent normal tissue samples collected from PDAC patients treated with gemcitabine after surgical tumor resection. To detect possible interaction between gene expression levels and to identify subgroups of patients a…

MaleOncologyCHOPEquilibrative nucleoside transporter 1BioinformaticsDeoxycytidineCohort StudiesPancreatic ductal adenocarcinomachemistry.chemical_compoundMedicine(all)Transcription Factor CHOPbiologyDCKGeneral MedicineMiddle AgedSurvival RateDisease ProgressionAdenocarcinomaFemaleMRP1DeoxycytidineMultidrug Resistance-Associated ProteinsCarcinoma Pancreatic Ductalmedicine.drugmedicine.medical_specialtyAntineoplastic AgentsAdenocarcinomaMalignancyhENT1General Biochemistry Genetics and Molecular BiologyEquilibrative Nucleoside Transporter 1Internal medicinemedicineHumansRNA MessengerSurvival rateAgedBiochemistry Genetics and Molecular Biology(all)business.industryResearchRECPAMmedicine.diseaseGemcitabineGemcitabinechemistrybiology.proteinPancreatic ductal adenocarcinoma hENT1 CHOP MRP1 DCK RECPAMbusinessTranscription Factor CHOPCHOP
researchProduct

The prognostic value of biological markers in paediatric Hodgkin lymphoma

2015

Abstract Background Many biological and inflammatory markers have been proposed as having a prognostic value at diagnosis of Hodgkin lymphoma (HL), but very few have been validated in paediatric patients. We explored the significance of these markers in a large population of 769 affected children. Patients and methods By using the database of patients enrolled in A.I.E.O.P. (Associazione Italiana di Emato-Oncologia Pediatrica) trial LH2004 for paediatric HL, we identified 769 consecutive patients treated with curative intent from 1st June 2004 to 1st April 2014 with ABVD (doxorubicin, bleomycin, vinblastine, and dacarbazine), or hybrid COPP/ABV (cyclophosphamide, vincristine, prednisone, pr…

MaleOncologyCancer ResearchPathologyTime FactorsDatabases Factualmedicine.medical_treatmenthodgkin lymphoma; paediatric; prognostic factorHodgkin lymphoma; Paediatric; Prognostic factor; Adolescent; Age Factors; Antineoplastic Combined Chemotherapy Protocols; Biomarkers Tumor; Child; Child Preschool; Databases Factual; Disease Progression; Disease-Free Survival; Female; Ferritins; Hodgkin Disease; Humans; Infant; Infant Newborn; Italy; Kaplan-Meier Estimate; Leukocyte Count; Male; Multivariate Analysis; Neoplasm Staging; Platelet Count; Predictive Value of Tests; Proportional Hazards Models; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; Blood Platelets; EosinophilsKaplan-Meier EstimateProcarbazineLeukocyte Countchemistry.chemical_compound0302 clinical medicineRisk FactorsPrednisoneAntineoplastic Combined Chemotherapy ProtocolsChildPrognostic factorTumorAge FactorsHodgkin DiseaseVinblastineTreatment OutcomeSettore MED/38 - PEDIATRIA GENERALE E SPECIALISTICAItalyOncologyPaediatricChild Preschool030220 oncology & carcinogenesisDisease ProgressionFemalemedicine.drugBlood Plateletsmedicine.medical_specialtyVincristineAdolescentDacarbazineBleomycinDisease-Free SurvivalDatabases03 medical and health sciencesPredictive Value of TestsInternal medicineBiomarkers TumormedicineHumansPreschoolFactualNeoplasm StagingProportional Hazards ModelsRetrospective StudiesChemotherapyPlatelet Countbusiness.industryInfant NewbornInfantNewbornEosinophilschemistryABVDFerritinsMultivariate AnalysisbusinessBiomarkersHodgkin lymphoma030215 immunologyEuropean Journal of Cancer
researchProduct

PICCA study: panitumumab in combination with cisplatin/gemcitabine chemotherapy in KRAS wild-type patients with biliary cancer—a randomised biomarker…

2017

Abstract Background Combination chemotherapy has shown benefit in the treatment of biliary cancer and further improvements might be achieved by the addition of a biological agent. We report here the effect of chemotherapy with the monoclonal EGFR antibody panitumumab as therapy for KRAS wild-type biliary cancer. Patients and methods Patients with advanced biliary tract cancer were randomised (2:1) to receive cisplatin 25 mg/m2 and gemcitabine 1000 mg/m2 on day 1 and day 8/q3w with (arm A) or without panitumumab (arm B; 9 mg/kg BW, i.v q3w). The primary end-point was the evaluation of progression-free survival (PFS) at 6 months. Secondary end-points included objective response rate (ORR), ov…

MaleOncologyCancer ResearchTime Factorsmedicine.medical_treatmentMedizinKaplan-Meier Estimatemedicine.disease_causeDeoxycytidine0302 clinical medicineRisk FactorsGermanyAntineoplastic Combined Chemotherapy ProtocolsMedicinePrecision MedicineAged 80 and overPanitumumabAntibodies MonoclonalCombination chemotherapyMiddle AgedIsocitrate DehydrogenaseBiliary Tract NeoplasmsTreatment OutcomeOncology030220 oncology & carcinogenesisDisease ProgressionBiomarker (medicine)Female030211 gastroenterology & hepatologyKRASmedicine.drugAdultmedicine.medical_specialtyAdolescentDisease-Free SurvivalProto-Oncogene Proteins p21(ras)Young Adult03 medical and health sciencesInternal medicineBiomarkers TumorHumansPanitumumabAgedCisplatinChemotherapybusiness.industryGene Expression ProfilingGemcitabineGemcitabineClinical trialMutationCisplatinbusinessEuropean Journal of Cancer
researchProduct

Mast cell targeting hampers prostate adenocarcinoma development but promotes the occurrence of highly malignant neuroendocrine cancers

2011

Abstract Mast cells (MC) are c-Kit–expressing cells, best known for their primary involvement in allergic reactions, but recently reappraised as important players in either cancer promotion or inhibition. Here, we assessed the role of MCs in prostate tumor development. In prostate tumors from both tumor-prone transgenic adenocarcinoma of the mouse prostate (TRAMP) mice and human patients, MCs are specifically enriched and degranulated in areas of well-differentiated (WD) adenocarcinoma but not around poorly differentiated (PD) foci that coexist in the same tumors. We derived novel TRAMP tumor cell lines, representative of WD and PD variants, and through pharmacologic stabilization or geneti…

MaleOncologyCancer Researchmedicine.medical_specialtyEpithelial-Mesenchymal TransitionMice TransgenicAdenocarcinomaBiologymedicine.disease_causeCell DegranulationMiceProstate cancerProstateCell Line TumorInternal medicineTumor MicroenvironmentmedicineMast CellAnimalsHumansMast CellsReceptors Tumor Necrosis Factor Member 25Tumor microenvironmentAdenocarcinoma; Animals; Carcinoma Neuroendocrine; Cell Degranulation; Cell Line Tumor; Disease Progression; Epithelial-Mesenchymal Transition; Humans; Male; Mast Cells; Matrix Metalloproteinase 9; Mice; Mice Inbred C57BL; Mice Transgenic; Prostatic Neoplasms; Proto-Oncogene Proteins c-kit; Receptors Tumor Necrosis Factor Member 25; Tumor Microenvironment; Cancer Research; OncologyAnimalProstatic NeoplasmsCancermedicine.diseasehumanitiesCarcinoma NeuroendocrineMice Inbred C57BLProto-Oncogene Proteins c-kitmedicine.anatomical_structureMatrix Metalloproteinase 9OncologyTumor progressionProstatic NeoplasmDisease ProgressionAdenocarcinomaCarcinogenesisHumanTramp
researchProduct

Cost-effectiveness analysis of pemetrexed versus docetaxel in the second-line treatment of non-small cell lung cancer in Spain: results for the non-s…

2010

Abstract Background The objective of this study was to conduct a cost-effectiveness evaluation of pemetrexed compared to docetaxel in the treatment of advanced or metastatic non-small cell lung cancer (NSCLC) for patients with predominantly non-squamous histology in the Spanish healthcare setting. Methods A Markov model was designed consisting of stable, responsive, progressive disease and death states. Patients could also experience adverse events as long as they received chemotherapy. Clinical inputs were based on an analysis of a phase III clinical trial that identified a statistically significant improvement in overall survival for non-squamous patients treated with pemetrexed compared …

MaleOncologyCancer Researchmedicine.medical_specialtyPathologyGuanineLung NeoplasmsCost-Benefit AnalysisPopulationDocetaxelPemetrexedlcsh:RC254-282Disease-Free SurvivalGlutamatesSurgical oncologyCarcinoma Non-Small-Cell LungCell Line TumorInternal medicineGeneticsCarcinomamedicineHumanseducationLung cancerneoplasmseducation.field_of_studybusiness.industryCarcinomaHistologylcsh:Neoplasms. Tumors. Oncology. Including cancer and carcinogensmedicine.diseaseMarkov Chainsrespiratory tract diseasesQuality-adjusted life yearTreatment OutcomePemetrexedOncologyDocetaxelSpainDisease ProgressionQuality of LifeFemaleTaxoidsQuality-Adjusted Life YearsbusinessResearch Articlemedicine.drugBMC Cancer
researchProduct

Restaging Patients With Hepatocellular Carcinoma Before Additional Treatment Decisions: A Multicenter Cohort Study

2018

Prognostic assessment of patients with hepatocellular carcinoma (HCC) at the time of diagnosis remains controversial and becomes even more complex at the time of restaging when new variables need to be considered. The aim of the current study was to evaluate the prognostic utility of restaging patients before proceeding with additional therapies for HCC. Two independent Italian prospective databases were used to identify 1,196 (training cohort) and 648 (validation cohort) consecutive patients with HCC treated over the same study period (2008-2015) who had complete restaging before decisions about additional therapies. The performance of the Italian Liver Cancer (ITA.LI.CA) prognostic score …

MaleOncologyDatabases FactualLiver cancer; non surgical therapy; prognostic system; surgical therapy; survivalhepatocellular carcinoma stage treatmentKaplan-Meier EstimateCohort StudiesLiver disease0302 clinical medicineMiddle AgedSorafenibPrognosisItaly030220 oncology & carcinogenesisCatheter AblationDisease ProgressionFemale030211 gastroenterology & hepatologysurgical therapyLiver cancerLiver cancermedicine.drugCohort studySorafenibmedicine.medical_specialtyCarcinoma HepatocellularSettore MED/12 - GASTROENTEROLOGIAClinical Decision-MakingRisk AssessmentsurvivalDisease-Free SurvivalStatistics Nonparametric03 medical and health sciencesnon surgical therapyInternal medicinemedicineHepatectomyHumansInfusions Intra-ArterialNeoplasm InvasivenessSurvival analysisAgedNeoplasm StagingRetrospective StudiesAnalysis of VarianceHepatologybusiness.industryprognostic systemReproducibility of ResultsCancerRetrospective cohort studymedicine.diseaseSurvival AnalysisbusinessProgressive disease
researchProduct

Specific TP53 and/or Ki-ras mutations as independent predictors of clinical outcome in sporadic colorectal adenocarcinomas: results of a 5-year Grupp…

2005

BACKGROUND: Although Ki-ras and TP53 mutations have probably been the genetic abnormalities most exhaustively implicated and studied in colorectal cancer (CRC) progression, their significance in terms of disease relapse and overall survival has not yet clearly been established. PATIENTS AND METHODS: A prospective study was carried out on paired tumor and normal colon tissue samples from a consecutive series of 160 previously-untreated patients, undergoing resective surgery for primary operable sporadic CRC. Mutations within the TP53 (exons 5-8) and Ki-ras (exon 2) genes were detected by PCR-SSCP analyses following sequencing. RESULTS: Mutation analyses of exons 5 to 8 of the TP53 gene showe…

MaleOncologyMultivariate analysisColorectal cancerpolymerase chain reactionmedicine.medical_treatmentLeucovorinColorectal Neoplasmmedicine.disease_causeBioinformaticsExonAntineoplastic Combined Chemotherapy ProtocolsProspective Studiesexongene mutationmultivariate analysiProspective cohort studysingle strand conformation polymorphism MeSH: Adenocarcinomaprotein p53 EMTREE medical terms: adultProto-Oncogene ProteinMutationarticleprotein domainclinical trialHematologyMiddle AgedagedItalypriority journalOncologyChemotherapy AdjuvantLymphatic MetastasisDisease ProgressionFemaleFluorouracilColorectal Neoplasmscancer tissueprognosiprospective studyHumansamplingmedicine.medical_specialtyfolinic acidgene sequenceAdenocarcinomarectum carcinomaProto-Oncogene Proteins p21(ras)outcomes researchProto-Oncogene ProteinsInternal medicinemedicineHumanscontrolled studyneoplasmsGeneNeoplasm StagingChemotherapyEMTREE drug terms: fluorouracillevamisoleAntineoplastic Combined Chemotherapy Protocolcontrolled clinical trialbusiness.industryfluorouracil; folinic acid; K ras protein; levamisole; protein p53 adult; aged; article; cancer tissue; clinical trial; codon; colon adenocarcinoma; colorectal surgery; controlled clinical trial; controlled study; exon; gene mutation; gene sequence; human; human cell; human tissue; Italy; major clinical study; male; multivariate analysis; oncology; outcomes research; polymerase chain reaction; prediction; priority journal; prognosis; prospective study; protein domain; rectum carcinoma; sampling; sequence analysis; single strand conformation polymorphism Adenocarcinoma; Aged; Antineoplastic Combined Chemotherapy Protocols; Chemotherapy Adjuvant; Colorectal Neoplasms; Disease Progression; Female; Fluorouracil; Humans; Leucovorin; Levamisole; Lymphatic Metastasis; Male; Middle Aged; Multivariate Analysis; Mutation; Neoplasm Staging; Prospective Studies; Proto-Oncogene Proteins; ras Proteins; Tumor Suppressor Protein p53 [EMTREE drug terms]human cellLymphatic Metastasipredictionras Proteinmedicine.diseasemajor clinical studyhuman tissueProto-Oncogene Proteins p21(ras)K ras proteinProspective Studiecolon adenocarcinomaMultivariate AnalysisMutationras Proteinscolorectal surgerysequence analysicodonTumor Suppressor Protein p53businessAnnals of Oncology
researchProduct

Immunohistochemical Expression of Ki-67 Antigen, Cox-2 and Bax/Bcl-2 in Prostate Cancer; Prognostic Value in Biopsies and Radical Prostatectomy Speci…

2005

Abstract Purposes: To elucidate the prognostic value of the immunohistochemical (IHC) expression of Bcl-2, Bax, Cox-2 and Ki-67 antigen in biopsy cores (C) and surgical specimens (SP) of prostate cancer (PC) and to determine the C to SP reproducibility. Material and methods: The IHC study was carried out in 91 patients operated by means of radical prostatectomy (RP) with available formalin-fixed paraffin-embedded material from both C and SP. Results: The IHC expression of Bcl-2 in C and SP was very low (5%). Bax was expressed in almost all the patients and did not show any prognostic value. We observed a good reproducibility between C and SP for all molecules except with Bax. In prostate C,…

MaleOncologymedicine.medical_specialtyPathologyBiopsyUrologymedicine.medical_treatmentDisease-Free SurvivalProstate cancerProstateInternal medicineBiopsyBiomarkers TumormedicineHumansAgedRetrospective Studiesbcl-2-Associated X ProteinProstatectomyUnivariate analysismedicine.diagnostic_testbiologyProstatectomybusiness.industryMembrane ProteinsProstatic NeoplasmsAnatomical pathologyMiddle AgedPrognosismedicine.diseaseImmunohistochemistryKi-67 Antigenmedicine.anatomical_structureProto-Oncogene Proteins c-bcl-2Cyclooxygenase 2Ki-67Multivariate AnalysisDisease Progressionbiology.proteinImmunohistochemistrybusinessEuropean Urology
researchProduct

A significant percentage of CD20-positive TILs correlates with poor prognosis in patients with primary cutaneous malignant melanoma

2014

MaleOncologymedicine.medical_specialtyPoor prognosisSkin NeoplasmsHistologyMultivariate analysisMEDLINEPathology and Forensic MedicineText miningInternal medicinemedicineHumansIn patientMelanomaCD20biologybusiness.industryMelanomaDisease progressionGeneral MedicineAntigens CD20Prognosismedicine.diseaseMultivariate AnalysisDisease Progressionbiology.proteinFemalebusinessHistopathology
researchProduct

Active Surveillance in Prostate Cancer: Role of Available Biomarkers in Daily Practice

2021

Prostate cancer (PCa) is the most commonly diagnosed cancer in men. The diagnosis is currently based on PSA levels, which are associated with overdiagnosis and overtreatment. Moreover, most PCas are localized tumours; hence, many patients with low-/very low-risk PCa could benefit from active surveillance (AS) programs instead of more aggressive, active treatments. Heterogeneity within inclusion criteria and follow-up strategies are the main controversial issues that AS presently faces. Many biomarkers are currently under investigation in this setting; however, none has yet demonstrated enough diagnostic ability as an independent predictor of pathological or clinical progression. This work a…

MaleOncologymedicine.medical_specialtyQH301-705.5clinical biomarkers030232 urology & nephrologyReviewIndependent predictorCatalysisInorganic Chemistry03 medical and health sciencesProstate cancer0302 clinical medicineInternal medicineDaily practicemedicineHumansBiology (General)Physical and Theoretical ChemistryOverdiagnosisWatchful WaitingQD1-999Molecular BiologyPathologicalSpectroscopybusiness.industryOrganic Chemistryactive surveillanceProstatic NeoplasmsCancerGeneral Medicinemedicine.diseaseprostate cancerComputer Science ApplicationsChemistryUrine biomarkers030220 oncology & carcinogenesisDisease Progressionrisk predictorsbusinessBiomarkersClinical progressionInternational Journal of Molecular Sciences
researchProduct